This phase II pilot study aims at evaluating the benefits and the risks of methylphenidate
(Concerta®) for the treatment of cocaine/crack dependence in terms of cocaine/crack use
reduction and adverse events.
Phase:
Phase 2
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)